Neurofibromatosis Clinical Trials

A listing of Neurofibromatosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 57 clinical trials
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

inhibitor of MEK1/2, which is expected to be a targeted therapy for the treatment of advanced solid tumors and neurofibromatosis type 1.

solid tumors
  • 07 Oct, 2022
  • 7 locations
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2)

This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with neurofibromatosis type 2 (NF2) with associated

experimental drug
nf2 gene
acoustic neuroma
  • 30 Jun, 2022
  • 6 locations
Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours (INSPECT)

Phase I and II study of the MEK inhibitor Selumetinib given twice daily on 5 out of 7 days in children with NF1 and inoperable plexiform neurofibromas or progressive/relapsed optic pathway

neutrophil count
measurable disease
renal function
tumor resection
  • 27 Feb, 2022
  • 1 location
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

mutations including BRAF V600 mutations or BRAF fusion/duplication, with or without neurofibromatosis type 1. Neurofibromatosis type 1 is an inherited genetic condition that causes tumors to grow on nerve

  • 07 Oct, 2022
  • 9 locations
Comparison of Gastrointestinal Motility in Healthy Children and Children With Constipation

aged 7 to 17 years: healthy children, chronically constipated children (ROM IV criteria), children with neurofibromatosis type 1 and finally children receiving chemotherapy (vincristin) for acute

Accepts healthy volunteers
gastrointestinal symptoms
chronic constipation
lymphoid leukemia
  • 09 Feb, 2022
  • 1 location
NF-1, Nutraceutical Intervention

The treatment plan is identical for all participants with the exception of the curcumin dose level that is assigned at study enrollment. Participants are instructed to take the curcumin and olive oil one after the other (order does not matter) twice a day on an empty stomach ideally 30 minutes …

  • 07 Oct, 2022
  • 1 location
Sunitinib in Treating Patients With Recurrent or Unresectable Meningioma Intracranial Hemangiopericytoma or Intracranial Hemangioblastoma

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying sunitinib to see how well it works in treating patients with recurrent or unresectable meningioma, intracranial hemangiopericytoma, or intracranial hemangioblastoma.

  • 07 Nov, 2020
  • 2 locations
Interventions for Reading Disabilities in NF1

Neurofibromatosis Type 1 (NF1) is a common genetic disorder that is associated with a four times greater risk of learning disabilities, including reading disabilities, and a deficiency of

renal impairment
brain tumors
psychiatric disorder
kidney failure
  • 09 Jul, 2022
  • 1 location
Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery

This phase I trial studies the side effects and the best dose of a vaccine therapy in treating patients with malignant peripheral nerve sheath tumor that cannot be removed by surgery (unresectable) or has come back after a period of improvement (recurrent). Vaccines made from a gene-modified virus may kill …

tumor cells
ct scan
measurable disease
absolute neutrophil count
  • 04 Oct, 2022
  • 1 location
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type 1. Selumetinib works by blocking some of the

giant cell astrocytoma
residual tumor
glomerular filtration rate
  • 07 Apr, 2023
  • 68 locations